STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis

被引:1
|
作者
Zhang, Wen-Di [1 ]
Hu, Dong-Mei [1 ]
Shi, Zhuang-E [1 ]
Wang, Qing-Xiang [1 ]
Zhang, Meng-Yu [1 ]
Liu, Jian-Yu [1 ]
Ji, Xiu-Li [2 ]
Qu, Yi-Qing [3 ,4 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Pulm & Crit Care Med, Shandong Key Lab Infect Resp Dis,Cheeloo Coll Med, Jinan, Peoples R China
[2] Jinan Tradit Chinese Med Hosp, Dept Pulm Dis, Jinan 250012, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Pulm & Crit Care Med, Shandong Key Lab Infect Resp Dis, Jinan, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Pulm & Crit Care Med, Wenhuaxi Rd 107, Jinan 250012, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
lung adenocarcinoma (LUAD); prognosis; epigenetic regulation; m6A modification; ferroptosis; immune infiltration; GENE-EXPRESSION; TGF-BETA; CELLS; IMMUNOTHERAPY; SUPPRESSION; SURVIVAL; TARGETS; LIPIDS; START;
D O I
10.7150/ijms.84566
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic reprogramming plays an important role in tumor progression and antitumor immunity. START domain-containing proteins (STARDs) are responsible for lipid metabolism. However, the underlying functions of STARDs in lung adenocarcinoma (LUAD) have not been clarified yet.Methods: Oncomine, UALCAN, TCGA and CPTAC were used to explore the expression landscape and clinicopathological characteristics of STARDs in LUAD. Diagnostic and prognostic values were assessed by Kaplan-Meier Plotter, Cox regression analysis, and ROC curve. GeneMANIA, GO, KEGG and GSEA were applied for exploring the potential biological functions. Epigenetic process, including mutation and m6A modification were analyzed by cBioPortal and TCGA. TIMER, TISIDB and TCGA cohort provided an immune signature. The correlation between STARDs expression and ferroptosis was analyzed by TCGA. Finally, the STARDs expression were confirmed by RT-qPCR and western blot.Results: STARD5/10/14 were overexpressed in LUAD compared with normal, while STARD4/7/8/11/12/13 were relatively low. STARD5/12/14 levels were positively related to clinical and lymph node stage. Survival analysis showed high STARD12 expression was associated with favorable overall survival, disease special survival as well as disease free survival, while STARD14 showed the opposite. GSEA analysis found STARD12 and STARD14 were associated with glycolysis, oxidative phosphorylation and tumor related signaling pathways. STARD12 co-expressed genes participated in cell cycle and DNA replication, and STARD14 were enriched in ECM-receptor interaction. Both STARD12 and STARD14 were corelated with epigenetic regulation, especially TP53 mutation and m6A modification. STARD12 expression was positively correlated with TMB level. The level of STARD12 was significantly associated with the abundance of infiltrating immune cells, including B cells, CD8+T cells, macrophages, dendritic cells, and chemokine, receptor, MHC, immunostimulatory related genes. STARD14 was negatively associated with the infiltration of CD8+T cells, while positively with CCL28 and immune checkpoints, including CTLA4 as well as PD-L2. In addition, STARD12/14 could regulate the ferroptosis related genes.Conclusion: STARD12 and STARD14 were expected to be potential biomarkers for LUAD, which were associated with epigenetic regulation, immune infiltration and ferroptosis.
引用
收藏
页码:1427 / 1447
页数:21
相关论文
共 42 条
  • [1] Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma
    Xia, Zhi
    Rong, Xueyao
    Dai, Ziyu
    Zhou, Dongbo
    FRONTIERS IN GENETICS, 2022, 13
  • [2] ADAM12 as a Clinical Prognostic Indicator Associated with Tumor Immune Infiltration in Lung Adenocarcinoma
    Pan, Junfan
    Huang, Zhidong
    Zhang, Yuan
    Xu, Yiquan
    DNA AND CELL BIOLOGY, 2022, 41 (04) : 410 - 423
  • [3] Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma
    Li, Jingyuan
    Liu, Xingyuan
    Cui, Zan
    Han, Guanying
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [4] ZC3H12D is a prognostic biomarker associated with immune cell infiltration in lung adenocarcinoma
    Gong, Wangang
    Dai, Wumin
    Wei, Haibin
    Chen, Yongyi
    Zheng, Zhiguo
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (10) : 6128 - +
  • [5] DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma
    Yang-Jie Wu
    Ai-Tao Nai
    Gui-Cheng He
    Fei Xiao
    Zhi-Min Li
    San-Yuan Tang
    Yan-Ping Liu
    Xiao-Hong Ai
    World Journal of Surgical Oncology, 19
  • [6] DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma
    Wu, Yang-Jie
    Nai, Ai-Tao
    He, Gui-Cheng
    Xiao, Fei
    Li, Zhi-Min
    Tang, San-Yuan
    Liu, Yan-Ping
    Ai, Xiao-Hong
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [7] BDNF is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and is associated with brain metastasis
    Yu, Qian
    Wang, Yitian
    Yi, Guangming
    Yang, Wendi
    Chen, Kehong
    Tan, Xiangwu
    Zhang, Xiaoyue
    Xu, Zaicheng
    Yang, Zhenzhou
    Peng, Yuan
    IMMUNOLOGY, 2023, 168 (02) : 320 - 330
  • [8] TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment
    He, Aoxiao
    Zhang, Rongguiyi
    Wang, Jiakun
    Huang, Zhihao
    Liao, Wenjun
    Li, Yong
    Wang, Cong
    Yang, Jun
    Feng, Qian
    Wu, Linquan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E129 - E140
  • [9] Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma
    Ye, Chenyang
    Lu, Yier
    Yuan, Zhijun
    Mi, Mi
    Qi, Lina
    Yuan, Ying
    Weng, Shanshan
    FRONTIERS IN GENETICS, 2022, 13
  • [10] Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting
    Jiao, Lijun
    Tao, Yujian
    Ding, Huizhen
    Wu, Feng
    Liu, Yantong
    Li, Chuang
    Li, Feifei
    3 BIOTECH, 2024, 14 (09)